EcosystèmeFrance

As of Monday, May 18, Biotech Finances will go live with a new version of its website and launch a mobile application. A redesign conceived to make access to content easier and to broaden its international reach, while maintaining a high value-added

TOP LINE

EcosystèmeInternational

We were worried about the FDA with arrivals (Vinay Prasad), departures (Richard Padzur, Vinay Prasad), reversals and returns (Vinay Prasad), then again resignations (Vinay Prasad), strange decisions and ever more indecision. But today the rag is burn

VCFrance

The healthcare venture firm closes its fourth biotech fund, up 35%, and confirms a still-minority strategy in Europe: combining company creation and early-stage investments.Kurma Partners announces the final closing of Biofund IV at €215M, versus €16

EcosystèmeFrance

Health research depends heavily on residual human biological samples, but it is today hindered by a bureaucracy deemed "disproportionate." Backed by the Observatoire du droit de la recherche en santé (ODRES), their appeal targets the CODECOH procedur

ESSENTIEL

EcosystèmeFrance

WORLD(United States/Medtech/Urology) - Rivermark Medical closes a $20M Series D led by Andera Partners, with support from existing investors and a strategic investor (undisclosed), to accelerate development of its FloStent system for benign prostatic

BiotechFrance

To finance the research programs of its vaccine candidates in asthma and food allergy, the company founded in 1993 has raised nearly €40M in the form of convertible bonds (Oceane) since its takeover in 2020. An innovative source of financing for this

TOP LINE

Photo: Alain Lamproye

EcosystèmeFrance

The French CRO specialized, among other things, in analyses for gene therapies can now analyze clinical samples coming from across the Atlantic.GenoSafe, a CRO originating from the AFM-Téléthon ecosystem, is developing its international positioning.

EcosystèmeFrance

As of Monday, May 18, Biotech Finances will go live with a new version of its website and launch a mobile application. A redesign conceived to make access to content easier and to broaden its international reach, while maintaining a high value-added

BiotechFrance

To finance the research programs of its vaccine candidates in asthma and food allergy, the company founded in 1993 has raised nearly €40M in the form of convertible bonds (Oceane) since its takeover in 2020. An innovative source of financing for this

HealthtechFrance

A major first for Ludocare. The young Lyon-based startup became, in early April, the first to obtain a favorable opinion from the Haute Autorité de santé (HAS) with a view to reimbursement for a digital therapy in France. The use of the device « JOE

VCFrance

The most common chronic disease in children, moderate to severe asthma remains imperfectly treated by current inhalation devices, leading to a high impact on school absenteeism and the quality of life of young patients. A population that has become a

ESSENTIEL

EcosystèmeFrance

WORLD(United States/Medtech/Urology) - Rivermark Medical closes a $20M Series D led by Andera Partners, with support from existing investors and a strategic investor (undisclosed), to accelerate development of its FloStent system for benign prostatic

IN THE SPOTLIGHT (Paris/Healthtech/Investment) - Lauxera Capital Partners closes its Lauxera Growth II fund at €520M, exceeding its initial target of €500M and doubling the size of its first vehicle. This growth equity fund targets 12 to 15 investmen

WORLD (United States/Pharma partnerships/R&D) – Parabilis Medicines forges a strategic collaboration with Regeneron around its Helicon™ peptide platform, a new class of stabilized alpha‑helical peptides capable of penetrating cells and targeting intr

WORLD(Australia/Medtech/Urology) - NinaMED launches with $13.75M in financing led by SPRIM Global Investments to develop and commercialize the NiNA System, a non‑invasive, at‑home, drug‑free neuromodulation device for overactive bladder (OAB), under

MONDE(United States/Medtech/Urology) - Rivermark Medical closes a $20M Series D round led by Andera Partners, with support from existing investors and a strategic investor (not disclosed), to accelerate development of its FloStent system for benign p

WORLD(United States/Healthtech/Preventive medicine) - PeterMD is opening its share capital to a majority takeover by the Lorient health fund (alongside Emanate) to accelerate the national deployment of its "Medicine 3.0" platform, a market estimated

(Rouen/Medtech/Cardiology) - Robocath has completed recruitment for its first “first‑in‑human” study on its next‑generation robotic platform for coronary angioplasty, conducted on 20 patients at the Centre Cardiologique du Nord (Saint‑Denis) with les